Back to top
more

Nivalis Therapeutics, Inc. (ALPN)

(Delayed Data from NSDQ)

$6.24 USD

6.24
7,474

-0.08 (-1.27%)

Updated May 3, 2019 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[ALPN]

Reports for Purchase

Showing records 1 - 20 ( 156 total )

Industry: Medical - Drugs

Record: 1

05/16/2024

Daily Note

Pages: 10

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 2

05/15/2024

Company Report

Pages: 5

Q1 Financials; Acquisition by VRTX Expected to Close by 2Q:24

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 3

04/11/2024

Company Report

Pages: 9

Vertex Steps Up with a Big Check; Alpine Acquired; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 4

04/11/2024

Daily Note

Pages: 12

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 5

04/11/2024

Company Report

Pages: 7

Call it ALPN Peak; VRTX to Acquire ALPN for $65/sh; D/G to Neutral

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 6

04/01/2024

Industry Report

Pages: 19

The Wedbush Monthly Check-Up: April 2024

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 7

03/21/2024

Company Report

Pages: 7

Translational Data Boost Our Enthusiasm to See What Povetacicept Can Do For Lupus Patients

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 8

03/21/2024

Daily Note

Pages: 5

Oh the Places Povetacicept Can Go; New Translational Data at SLEuro

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 9

03/19/2024

Daily Note

Pages: 8

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 10

03/19/2024

Company Report

Pages: 6

Q4 Financials; All Eyes on RUBY-3 Update at WCN

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 11

03/19/2024

Company Report

Pages: 7

2023 Results; Povetacicept Program Revs Up With Multiple Upcoming Catalysts

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 12

03/15/2024

Industry Report

Pages: 10

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 13

03/14/2024

Company Report

Pages: 5

Updated RUBY-3 Data at WCN; Increasing PT to $47

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 14

03/14/2024

Daily Note

Pages: 10

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 15

01/26/2024

Daily Note

Pages: 13

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 16

01/26/2024

Company Report

Pages: 8

The Class Gets High Marks; Povetacicept Ahead of the Curve

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 17

12/22/2023

Company Report

Pages: 7

Povetacicept Remains Primary Focus as AbbVie Amends Acazicolcept Option Agreement; Price Target Upped to $32

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 18

12/22/2023

Daily Note

Pages: 7

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 19

12/22/2023

Daily Note

Pages: 4

Acazicolcept Study Cut Short; Sharpening Focus on Povetacicept Opportunities

Provider: Wedbush Securities Inc.

Analyst: DRISCOLL R

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 20

12/14/2023

Industry Report

Pages: 44

Could 2024 Finally Be Biotech''s Breakthrough Year?

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 50.00

Research Provided by a Third Party